An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
“What the hell does that mean?”
Consider. It’s a word I’ve used in many instances and with many patients. Yet, I never really stopped to think about just how little that says.
"Don't ever let a health-care professional look at you, tell you something and walk away ... you should never be (thinking) 'What did he say? I don't know,'''
Costs were mainly due to hospital admissions and, to a lesser extent, physician services.
In Canada, medically necessary health care is funded for all permanent residents through universal public health care insurance plans managed by provincial/territorial governments. In Ontario, residents are covered by the Ontario Ministry of Health and Long-Term Care (MOHLTC). This includes services provided in hospital and by physicians as well as other services. In many cases, once care is provided outside of hospitals, patients may be required to pay out-of-pocket for direct medical costs, such as prescription drugs or home care.
#1: United States
| |
#2: Netherlands
| |
#3: Germany
| |
#4: Canada
| |
#5: Portugal
| |
#6: France
| |
#7: Romania
| |
#8: Russia
| |
#9: Brazil
| |
#10: Italy
|
The two national health charities plan to amalgamate under the Canadian Cancer Society banner.
The Canadian Cancer Society also announced on Friday the appointment of Lynne Hudson as President and CEO, effective immediately.~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
In a comparative analysis, the authors previously described the similarities in the genetic and epigenetic events of breast and ovarian cancer suggesting a common epigenetic origin. They have shown before that combination of histone deacetylase inhibitors with calpain inhibitor produced enhanced growth inhibition and cell death in different types of breast cancer cells including triple negative breast cancer cells as they observed in different types of ovarian cancer cells in this study.
...They are also disadvantaged by a Byzantine hospital-funding formula that is not nimble enough to respond to such an extraordinary spike in traffic at one cluster of hospitals, according to a June, 2016, report commissioned by the local health authority that oversees Toronto.
“EDs can’t survive in this way,” Dr. Chopra said. “You’ll have staff dissatisfaction, patient dissatisfaction, poor patient outcomes. We have been extremely lucky that somebody hasn’t died.”...
The contribution of genomic information to precision cancer medicine
|
Typical example(s)
|
|---|---|
Cancer risk reduction
|
Genetic testing of BRCA1/BRCA2 in hereditary breast cancer and ovarian cancer; MSH2/MSH6/MLH in hereditary nonpolyposis colorectal cancer; RB1 in retinoblastoma
|
Early detection
|
Liquid biopsies
|
Accurate diagnosis
|
Using molecular markers in tumor classification
|
Targeted therapy
|
EGFR inhibitors to treat EGFR mutation carriers; BRAF inhibitors to treat BRAF V600E carriers; Tyrosine-kinase inhibitor to treat BCR–ABL fusion protein
|
Frequently written off as psychological, pain usually amenable to treatment.
Kennedy said the most common cause of sexual pain in women with cancer is low estrogen levels, which, in fact, has a physical basis and typically results from hormonal therapy, ovary removal or radiation to the pelvic region.
We suggest that more attention is needed for the impact of pain during endometrial sampling and use of painkillers should be encouraged (NSAID’s). Other less painful methods such as combining with colonoscopy under conscious sedation [18, 19], liquid biopsies in blood [23] and analysing endometrial tissue to detect endometrial cancer by tampons [24] should be explored to omit painful repetitive endometrial sampling in women with LS.
Caution should be taken when interpreting small studies with very large treatment effects.
An analysis of 19 studies found no link between breast cancer risk and diets high in GI beyond what could occur by chance.
There are suggestions that localization of CC (right CC [RCC]3,4 sided up to splenic flexure and left CC [LCC], including descending, and sigmoid and/or rectosigmoid cancers) potentially influences prognosis owing to differing biological features. Clinical presentation is also different: iron deficiency anemia from occult blood loss is more prevalent in patients with right-sided CCs; conversely, hematochezia and change in bowel habits is a more common presenting symptom for left-sided CCs.3 From a molecular point of view, RCC and LCC are 2 different entities, with RCC associated with defective mismatch repair (MMR) genes (Lynch Syndrome), mutations of KRAS and BRAF, and microRNA-31, whereas LCC is associated with CIN, p53, NRAS, microRNA-146a, microRNA-147b, and microRNA-1288.4
In this systematic review and meta-analysis, we evaluated the independent prognostic value of site of primary tumor (left-sided vs right-sided primary location) in patients with cancer of the colon.
Tumors arising on the right side of the colon, in fact, seem to follow different molecular pathways of oncogenesis. These RCCs more commonly are diploid and characterized by mucinous histology, high microsatellite instability, CpG island methylation, and BRAF mutations.81- 85
In stage II completely resected CC, the presence of MSI has been associated with a more favorable prognosis and a lack of benefit from fluorouracil-based adjuvant chemotherapy.84 More recently, Sinicrope et al5 evaluated the prognostic impact of deficient DNA MMR in patients with stage III enrolled in a randomized trial of FOLFOX-based adjuvant chemotherapy and found that among deficient MMR cancers only proximal tumors had favorable outcome.
insurance status was not significant
Among cancer survivors, if more than one cancer was reported, we chose the cancer type corresponding to the most recent cancer diagnosis in our analysis.....Consistent with previous research, cancers with a relative 5-year survival of < 25% (ie, esophagus, liver, gall bladder, lung, pancreas, and stomach) were combined as “short survival cancers.”23
Among cancer survivors, the lowest percentages of medication use for anxiety (ie, < 10%) were seen in those with a history of prostate cancer, whereas the highest rates (ie, > 20%) were seen in survivors who were 40 to 64 years old, those who were never married, and those who had a history of ovarian, uterine, or short survival cancers.~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
